Patents by Inventor Malcolm Peet

Malcolm Peet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HIGHLY PURIFIED ETHYL EPA AND OTHER EPA DERIVATIVES
    Publication number: 20140073692
    Abstract: A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA is provided.
    Type: Application
    Filed: September 16, 2013
    Publication date: March 13, 2014
    Applicant: AMARIN PHARMACEUTICALS IRELAND LIMITED
    Inventors: Malcolm Peet, Krishna S. Vaddadi
  • HIGHLY PURIFIED ETHYL EPA AND OTHER EPA DERIVATIVES
    Publication number: 20120195963
    Abstract: A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA is provided.
    Type: Application
    Filed: April 4, 2012
    Publication date: August 2, 2012
    Applicant: AMARIN PHARMACEUTICALS IRELAND LIMITED
    Inventors: Malcolm Peet, Krishna S. Vaddadi
  • Highly purified ethyl EPA and other EPA derivatives
    Patent number: 8188146
    Abstract: A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA is provided.
    Type: Grant
    Filed: March 20, 2008
    Date of Patent: May 29, 2012
    Assignee: Amarin Corporation Plc.
    Inventors: Malcolm Peet, Krishna S. Vaddadi
  • HIGHLY PURIFIED ETHYL EPA AND OTHER EPA DERIVATIVES
    Publication number: 20110065793
    Abstract: A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA is provided.
    Type: Application
    Filed: November 22, 2010
    Publication date: March 17, 2011
    Applicant: AMARIN CORPORATION Plc.
    Inventors: Malcolm Peet, Krishna S. Vaddadi
  • Highly Purified Ethyl EPA and Other EPA Derivatives
    Publication number: 20080200547
    Abstract: A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA is provided.
    Type: Application
    Filed: March 20, 2008
    Publication date: August 21, 2008
    Inventors: Malcolm Peet, Krishna S. Vaddadi
  • Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders
    Publication number: 20060252833
    Abstract: A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA is provided for the treatment of a psychiatric or central nervous disorder. The preparation may be administered with conventional drugs to treat psychiatric or central nervous disorders to improve their efficacy or reduce their side effects.
    Type: Application
    Filed: February 24, 2006
    Publication date: November 9, 2006
    Inventors: Malcolm Peet, Krishna Vaddadi
  • Highly purified ethyl EPA and other EPA derivatives for treatment of huntington's disease
    Patent number: 7119118
    Abstract: A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA is provided for the treatment of a psychiatric or central nervous disorder. The preparation may be administered with conventional drugs to treat psychiatric or central nervous disorders to improve their efficacy or reduce their side effects.
    Type: Grant
    Filed: July 10, 2002
    Date of Patent: October 10, 2006
    Assignee: Laxdale Limited
    Inventors: Malcolm Peet, Krishna S Vaddadi
  • Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders
    Publication number: 20040162348
    Abstract: A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA is provided for the treatment of a psychiatric or central nervous disorder. The preparation may be administered with conventional drugs to treat psychiatric or central nervous disorders to improve their efficacy or reduce their side effects.
    Type: Application
    Filed: February 12, 2004
    Publication date: August 19, 2004
    Applicant: Laxdale Limited
    Inventors: Malcolm Peet, Krishna S. Vaddadi
  • Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders
    Patent number: 6689812
    Abstract: A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA is provided for the treatment of a psychiatric or central nervous disorder. The preparation may be administered with conventional drugs to treat psychiatric or central nervous disorders to improve their efficacy or reduce their side effects.
    Type: Grant
    Filed: December 14, 2001
    Date of Patent: February 10, 2004
    Assignee: Laxdale Limited
    Inventors: Malcolm Peet, Krishna S Vaddadi
  • Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders
    Publication number: 20020193439
    Abstract: A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA is provided for the treatment of a psychiatric or central nervous disorder. The preparation may be administered with conventional drugs to treat psychiatric or central nervous disorders to improve their efficacy or reduce their side effects.
    Type: Application
    Filed: July 10, 2002
    Publication date: December 19, 2002
    Applicant: Laxdale Limited
    Inventors: Malcolm Peet, Krishna S. Vaddadi
  • Highly purified EPA and other EPA derivatives for psychiatric and neurological disorders
    Publication number: 20020183389
    Abstract: A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA is provided for the treatment of a psychiatric or central nervous disorder. The preparation may be administered with conventional drugs to treat psychiatric or central nervous disorders to improve their efficacy or reduce their side effects.
    Type: Application
    Filed: June 19, 2002
    Publication date: December 5, 2002
    Applicant: Laxdale Limited
    Inventors: Malcolm Peet, Krishna S. Vaddadi
  • Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders
    Publication number: 20020077361
    Abstract: A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA is provided for the treatment of a psychiatric or central nervous disorder. The preparation may be administered with conventional drugs to treat psychiatric or central nervous disorders to improve their efficacy or reduce their side effects.
    Type: Application
    Filed: December 14, 2001
    Publication date: June 20, 2002
    Applicant: Laxdale Limited
    Inventors: Malcolm Peet, Krishna S. Vaddadi
  • Highly purified EPA for treatment of schizophrenia and related disorders
    Patent number: 6384077
    Abstract: A pharmaceutical preparation comprising EPA in an appropriately assimilable form where of all the fatty acids present in the preparation at least 90%, and preferably at least 95%, is in the form of EPA and where less than 5%, and preferably less than 3%, is in the form of DHA is provided for the treatment of a psychiatric or central nervous disorder. The preparation may be administered with conventional drugs to treat psychiatric or central nervous disorders to improve their efficacy or reduce their side effects.
    Type: Grant
    Filed: January 27, 2000
    Date of Patent: May 7, 2002
    Assignee: Laxdale Limited
    Inventors: Malcolm Peet, Krishna S Vaddadi